Drugs / 2-(5-fluoro-pentyl)-2-methyl-malonic-acid
2-(5-fluoro-pentyl)-2-methyl-malonic-acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00805636 | Nov 2008 → Oct 2010 | metastatic malignant neoplasm in the brain | Aposense Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-(5-fluoro-pentyl)-2-methyl-malonic-acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00805636 ↗ |
| Modality | Diagnostic / imaging agent | “as a PET Imaging Radiotracer” NCT00805636 ↗ |
| Route | Intravenous | “will be administered as an intravenous bolus injection” NCT00805636 ↗ |